A report of a suspected adverse reaction is never just a piece of data to be entered into a system. It may come from a physician, a patient, a digital channel, or a distributor, and it must be assessed, coded, followed up, and managed within defined timelines.
In pharmacovigilance outsourcing for pharmaceutical companies, the key challenge is not simply delegating operational activities, but maintaining control, traceability, and scientific consistency throughout every step of the process.
When pharmacovigilance outsourcing creates value
Outsourcing can involve specific activities, such as case processing, scientific literature monitoring, and follow-up management, or it can extend to the entire pharmacovigilance system.
The main advantage is immediate access to specialized expertise without the need to build and maintain every required role internally. This allows companies to manage workload peaks, new product launches, portfolio expansions, and regulatory changes while maintaining operational continuity and a strong focus on quality.
However, outsourcing does not transfer the Marketing Authorization Holder’s (MAH) ultimate responsibility. The MAH remains accountable for system compliance, supplier oversight, and the adequacy of decisions made.
For this reason, outsourced services must be governed by standard operating procedures, pharmacovigilance agreements, escalation pathways, and measurable performance indicators.
Pharmacovigilance outsourcing for pharmaceutical companies: choosing the right scope
The first decision concerns the scope of activities to be outsourced.
A modular model is appropriate when a company already has an established pharmacovigilance function and requires support for specific activities, such as backlog management, product launches, or temporary resource coverage.
A full-service model, on the other hand, may be more suitable when the pharmacovigilance function needs to be established, reorganized, or managed through continuous external support.
Using multiple suppliers for different activities can increase complexity. When Medical Information, scientific literature monitoring, pharmacovigilance, and regulatory affairs operate without a coordinated approach, the risk of duplication, delays, and inconsistent interpretations increases.
A partner with integrated expertise can help reduce these discontinuities while maintaining clear roles, responsibilities, and decision-making boundaries.
Selection criteria beyond operational capacity
Resource availability is essential, but it is not sufficient for evaluating a pharmacovigilance provider. In pharmacovigilance, a classification error, inconsistent coding, or incomplete follow-up can lead to regulatory and reputational consequences.
Supplier selection should evaluate at least four key areas:
- Demonstrated expertise in products, therapeutic areas, and markets relevant to the company.
- Quality of the quality system, including SOPs, training records, deviation management, and CAPA processes.
- Ability to manage information flows using validated systems, access controls, and audit trails.
- Governance model, including escalation procedures, reporting, KPIs, and support during audits or inspections.
It is also important to assess business continuity capabilities. The partner should be able to demonstrate how sudden increases in case volume, system outages, or the absence of key personnel are managed.
Governance: control cannot be outsourced
An effective partnership begins before operational activities start. The transition phase should include a structured transfer of information related to products, safety profiles, company procedures, triage criteria, escalation contacts, and system access.
The Safety Data Exchange Agreement (SDEA), or equivalent agreements, should clearly define responsibilities and reporting timelines, avoiding ambiguity in the management of special situations such as medication errors, lack of efficacy cases, or reports originating from non-promotional programs.
Routine governance activities should also monitor timeliness, data completeness, follow-up activities, deviations, quality control, and compliance with reporting requirements.
Every activity must be fully traceable during an audit or inspection through clear evidence, including the source and date of receipt, assessments performed, document versions, approvals, and corrective actions.
Integrating pharmacovigilance and Medical Information
The quality of information often depends on the first point of contact.
A Medical Information professional must respond appropriately to a scientific inquiry while also recognizing potential safety information. This requires dedicated training, clear procedures, and timely transfer of safety reports.
Integration between pharmacovigilance, Medical Information, literature research, and medical writing reduces the risk of inconsistent information and improves process continuity.
Outsourcing can therefore strengthen a pharmacovigilance system when the partner operates as a qualified extension of the internal team. Clear roles, transparent processes, and structured governance make it possible to maintain quality, compliance, and control, even during periods of increased operational pressure.